Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation
Abstract
We examined whether patients exhibiting withdrawal-emergent dyskinesia (WE-D) represent a group vulnerable to subsequent development of tardive dyskinesia (TD). WE-D was defined as moderate abnormal movements during antipsychotic withdrawal in persons without persistent TD. We assessed patients with schizophrenia-spectrum illness participating in withdrawal from antipsychotic medication. Patients with WE-D were compared to those without dyskinesia and to those with persistent TD. Clinical measures included duration of illness and antipsychotic exposure, negative symptoms, and neurologic soft signs. We hypothesized that WE-D patients would not differ from persistent-TD patients across the above variables, but would differ from non-TD patients. Patients without TD significantly differed from persistent TD in duration of illness, medication exposure and neurologic soft signs. WE-D did not differ from TD across these measures. No-TD patients also showed less duration of medication exposure and neurologic soft signs than those with WE-D.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Motor withdrawal symptoms have a reported incidence of 31%-50% after abrupt FGA withdrawal, following long-term treatment.
“Motor withdrawal symptoms have a reported incidence of 31%–50% after abrupt FGA withdrawal, following long-term treatment.29–31”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [29]
Cites
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407 · see citing works
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,706 · see citing works
Molecular pathology of schizophrenia: more than one disease process?
Crow, T. J. (1980) · BMJ · doi:10.1136/bmj.280.6207.66 · Cited by 1,863 · see citing works
The Comprehensive Assessment of Symptoms and History (CASH)
Andreasen, N. C. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080023004 · Cited by 1,314 · see citing works
Self-citationResearch diagnoses for tardive dyskinesia.
Schooler, N. R., & Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 951 · see citing works
The Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., et al. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 303 · see citing works
Schen, R. J. (1973) · The Lancet · doi:10.1016/s0140-6736(73)90897-0 · Cited by 277 · see citing works
Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors
KANE, J. M., WOERNER, M., & LIEBERMAN, J. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808001-00010 · Cited by 266 · see citing works
Integrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., et al. (1986) · PubMed · Cited by 207 · see citing works
Withdrawal syndromes associated with antipsychotic drugs
Gárdos, G., Jo, C., & Tarsy, D. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1321 · Cited by 192 · see citing works
Jeste, D. V., & Caligiuri, M. P. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.2.303 · Cited by 191 · see citing works
Para-amino-salicylic acid in pulmonary tuberculosis.
Nagley, M. M., & Mh, L. (1949) · PubMed · Cited by 187 · see citing works
Freer, C. B. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91039-6 · Cited by 152 · see citing works
The Prevalence of Tardive Dyskinesia
Woerner, M. G., Kane, J. M., Lieberman, J. A., et al. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199102000-00005 · Cited by 146 · see citing works
γ-Acetylenic GABA in Tardive Dyskinesia
Casey, D. E. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780250062007 · Cited by 110 · see citing works
Miller, D. D., Arndt, S. V., & Andreasen, N. C. (1993) · Comprehensive Psychiatry · doi:10.1016/0010-440x(93)90002-l · Cited by 107 · see citing works
Self-citationAbnormal Involuntary Movements in Schizophrenia
Crow, T. J., Cross, A. J., Johnstone, E. C., et al. (1982) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198210000-00010 · Cited by 105 · see citing works
ALPHA-TOCOPHEROL IN TARDIVE DYSKINESIA
Lohr, J. B., Cadet, J. L., Lohr, M., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92878-9 · Cited by 99 · see citing works
Glazer, W. M., Bowers, M. B., Charney, D. S., & Heninger, G. R. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90034-6 · Cited by 43 · see citing works
DILTIAZEM FOR TARDIVE DYSKINESIA
Ross, J. L., Mackenzie, T. B., Hanson, D. R., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90080-8 · Cited by 39 · see citing works
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design
Dixon, L. B., Thaker, G. K., Conley, R. R., Ross, D. E., Cascella, N. G., & Tamminga, C. A. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90061-m · Cited by 38 · see citing works
Negative Symptoms, Tardive Dyskinesia and Depression in Chronic Schizophrenia
Barnes, T. R. E., Liddle, P. F., Curson, D. A., et al. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291605 · Cited by 34 · see citing works
Effect of Antipsychotic Withdrawal on Negative Symptoms in Schizophrenia
Miller, D. D., Flaum, M. A., Arndt, S. V., Fleming, F. W., & Andreasen, N. C. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.31 · Cited by 32 · see citing works
Self-citationNegative Symptoms as a Risk Factor for Tardive Dyskinesia in Schizophrenia
Liddle, P. F., Barnes, T. R. E., Speller, J. C., et al. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.6.776 · Cited by 29 · see citing works
PLATELET MONOAMINE OXIDASE AND PLASMA DOPAMINE β-HYDROXYLASE IN TARDIVE DYSKINESIA
Jeste, D. V., Phelps, B. H., Rl, W., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92201-3 · Cited by 13 · see citing works
Perényi, A., Frecska, E., Bagdy, G., & Révai, K. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb02636.x · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Lerner, A., & Klein, M. (2019) · Brain Communications · doi:10.1093/braincomms/fcz025 · Cited by 89 · see citing works
Effects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52 · see citing works
Eserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15 · see citing works
- Authors
- Schultz, S. K., Miller, D. D., Arndt, S., Ziebell, S., Gupta, S., & Andreasen, N. C.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Schultz, Susan K.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 1995-12
- Volume
- 38
- Issue
- 11
- Pages
- 713-719
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2155742044
- Cited by
- 29
- References
- 26
- Citations by year
- 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 2 · 2015: 1 · 2013: 2
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 40856, MH-31593, MH-43271, R01MH040856)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- tardive dyskinesia, antipsychotic discontinuation, schizophrenia, antipsychotic withdrawal, negative symptoms, disease duration
- MeSH terms
- Adolescent, Adult, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged, Movement, Schizophrenia, Schizophrenic Psychology, Substance Withdrawal Syndrome, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review